Physician profile
Florette Dorvil
NPI 1912563057
$4,590.07
in general payments reported to CMS, 2019-2025
24 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $699 · 2022: $944 · 2023: $844 · 2024: $988 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,772 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,772.00 |
| Education | $174.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $913.86 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $657.98 | 2021-2025 | Breztri, Farxiga, Fasenra |
| Abbvie INC. | $633.93 | 2021-2025 | |
| Novo Nordisk INC | $414.45 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $403.57 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $268.93 | 2022-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $254.78 | 2023-2025 | |
| Exact Sciences Corporation | $209.14 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.50 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $95.71 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $72.33 | 2023-2024 | Gemtesa |
| Noven Therapeutics, LLC | $69.44 | 2022 | |
| Sunovion Pharmaceuticals INC. | $64.75 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $50.57 | 2021 | |
| Lundbeck LLC | $48.78 | 2025 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $45.34 | 2021 | |
| Hologic Sales and Service, LLC | $41.95 | 2023-2025 | Thinprep 2000 Processor, Aptima |
| Braeburn INC. | $32.71 | 2025 | Brixadi |
| Biohaven Pharmaceutical Holding Company LTD. | $27.38 | 2022 | |
| Dexcom, INC. | $26.89 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $23.15 | 2025 | |
| Viiv Healthcare Company | $22.25 | 2024 | Dovato |
| Janssen Pharmaceuticals, INC | $21.95 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Florette Dorvil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.